Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published July 2019
  • Article
  • Info & Metrics
  • PDF
Loading

Mechanisms of acquired resistance to BET-PROTACs

Zhang et al. Page 1302

PROTACs are bifunctional molecules that hijack endogenous E3 ubiquitin ligases to induce degradation of protein of interest. With the PROTAC technology progressing rapidly towards therapeutic applications, it would be important to understand whether and how resistance to these novel agents may emerge. Using BET-PROTACs as a model system, Zhang and colleagues demonstrate that resistance to both VHL- and CRBN-based PROTACs was primarily caused by genomic alterations that compromise core components of the relevant E3 ligase complexes. This study reveals a novel resistance mechanism distinct from current targeted therapies and lay the foundation for future investigations.

Alpha-particle therapy for the treatment of neuroblastoma

Makvandi et al. Page 1195

Neuroblastomas are highly radiosensitive, which opened the door for the development of beta-emitting radiotherapeutics to treat tumors. Beta particles are limited, however, in their ability to introduce DNA damage to single cells or micrometastatic clusters. Alpha particles deliver high amounts of linear energy transfer, depositing their energy over a short path-lengths. Makvandi and colleagues designed a PARP-1-targeted, astatine-211 (211At)-conjugated radiopharmaceutical ([211At]MM4). [211At]MM4 showed a durable anti-tumor response in a murine neuroblastoma xenograft. Moreover, there was a unique drug target up-regulation that adds a benefit to fractionated doses of [211At]MM4. Taken together, the study demonstrates the capability of targeting chromatin with alpha emitters through PARP-1 with broad implications in cancer therapy.

Preclinical characterization of NAE inhibitor TAS4464

Yoshimura et al. Page 1205

NEDD8 conjugation is a post-translational protein modification, and its regulation is related to cancer growth and survival. Yoshimura and colleagues reported the biological activities of TAS4464, a novel highly potent NAE selective inhibitor. TAS4464 inactivated the cullin-RING E3 ubiquitin ligases and consequently accumulated its substrates, such as p21, CDT1, and phosphorylated-IkBα. Weekly administration of TAS4464 showed prominent antitumor activities in human tumor xenograft models with a long duration of action within tumors. The use of longer-acting NAE inhibitor in intermittent dosing regimens has the potential to exert antitumor activity while minimizing the toxicity with less exposure on normal tissues.

Dual role of TGFβ in CRC

Siraj et al. Page 1312

In Saudi Arabia, colorectal cancer (CRC) presents the number one cancer affecting males and is marked by tumors that are more aggressive and present with higher stages. To combat this, Siraj and colleagues investigated the role of the Smad4/TGFβ axis in generating aggressive phenotypes in Saudi CRC. They demonstrate that Smad4 alterations can identify patients at a late stage (Dukes' C CRC) and at a high risk for recurrence after surgery and 5-FU chemotherapy. Furthermore, they outline the dependence of chemoresistance in Smad-deficient cells on KLF5 in TGFβ-stimulated conditions, highlighting the potential of KLF5 inhibition in CRC treatment.

  • ©2019 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 18 (7)
July 2019
Volume 18, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Ther July 1 2019 (18) (7) 1183;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Ther July 1 2019 (18) (7) 1183;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Mechanisms of acquired resistance to BET-PROTACs
    • Alpha-particle therapy for the treatment of neuroblastoma
    • Preclinical characterization of NAE inhibitor TAS4464
    • Dual role of TGFβ in CRC
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement